Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: Optimal timing and dosing of the drug

Nephrology Dialysis Transplantation

Volumn 26, Issue 8, 2011, Pages 2445-2453

  Meijer, E ^a   Gansevoort, R T ^a   De Jong, P E ^a   Van Der Wal, A M ^b   Leonhard, W N ^b   De Krey, S R ^b   Van Den Born, J ^a   Mulder, G M ^a   Van Goor, H ^a   Struck, J ^c   De Heer, E ^b   Peters, D J M ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c BRAHMS AG   (Germany)

Author keywords

ADPKD; disease stage; drug dose; PKD; vasopressin V2 receptor antagonist

Indexed keywords

AQUAPORIN 2; MEGALIN; MOZAVAPTAN; POLYCYSTIN 1; TAMM HORSFALL GLYCOPROTEIN; TAMOXIFEN; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V2 RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG MEGADOSE; EARLY INTERVENTION; FEMALE; GENE DELETION; KIDNEY EPITHELIUM; KIDNEY MASS; KIDNEY POLYCYSTIC DISEASE; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PKD1 GENE; PRIORITY JOURNAL; RENAL PROTECTION; TREATMENT DURATION; TREATMENT OUTCOME;

ANIMALS; BENZAZEPINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; KIDNEY; MALE; MICE; MICE, KNOCKOUT; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PROTEIN KINASE C; RECEPTORS, VASOPRESSIN;

EID: 79961070445     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr069     Document Type: Article

References (36)

1. Gabow PA. Autosomal dominant polycystic kidney disease. N Engl J Med 1993;329:332-342 (Pubitemid 23210687)
2. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007;369:1287-1301 (Pubitemid 46552051)
3. Peters DJ, Sandkuijl LA. Genetic heterogeneity of polycystic kidney disease in Europe. Contrib Nephrol 1992;97:128-139
4. Polycystic kidney disease. The complete structure of the PKD1 gene and its protein. The International Polycystic Kidney Disease Consortium. Cell 1995;81:289-298
5. Yamaguchi T, Pelling JC, Ramaswamy NT et al. cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int 2000;57:1460-1471 (Pubitemid 30207906)
6. Grantham JJ. Lillian Jean Kaplan International Prize for advancement in the understanding of polycystic kidney disease. Understanding polycystic kidney disease: a systems biology approach. Kidney Int 2003;64:1157-1162 (Pubitemid 37153779)
7. Belibi FA, Reif G, Wallace DP et al. Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int 2004;66:964-973 (Pubitemid 39120999)
8. Wang X, Wu Y, Ward CJ et al. Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol 2008;19:102-108
9. Gattone VH, Wang X, Harris PC et al. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 2003;9:1323-1326 (Pubitemid 37279858)
10. Torres VE, Wang X, Qian Q et al. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 2004;10:363-364 (Pubitemid 38508512)
11. Wang X, Gattone V, Harris PC et al. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 2005;16:846-851 (Pubitemid 41710293)
12. Nagao S, Nishii K, Katsuyama M et al. Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol 2006;17:2220-2227 (Pubitemid 44141912)
13. Torres VE, Meijer E, Bae KT et al. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes) 3/4 study. Am J Kidney Dis 2011
14. Grantham JJ, Cook LT, Wetzel LH et al. Evidence of extraordinary growth in the progressive enlargement of renal cysts. Clin J Am Soc Nephrol 2010;5:889-896
15. Ohnishi A, Orita Y, Takagi N et al. Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men. J Pharmacol Exp Ther 1995;272:546-551
16. Chapman AB, Torres VE, Grantham JJ et al. A Phase IIB pilot study of the safety and efficacy of tolvaptan, a vasopressin V2 receptor antagonist (V2RA) in patients with ADPKD [abstract]. J Am Soc Nephrol 2005
17. Lantinga-van Leeuwen IS, Leonhard WN, van de Wal A et al. Transgenic mice expressing tamoxifen-inducible Cre for somatic gene modification in renal epithelial cells. Genesis 2006;44:225-232 (Pubitemid 43877466)
18. Lantinga-van Leeuwen IS, Leonhard WN, van der Wal A et al. Kidney-specific inactivation of the Pkd1 gene induces rapid cyst formation in developing kidneys and a slow onset of disease in adult mice. Hum Mol Genet 2007;16:3188-3196 (Pubitemid 350131335)
19. Morgenthaler NG, Struck J, Alonso C et al. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006;52:112-119 (Pubitemid 43032474)
20. Rose BD. Clinical Physiology of Acid-Base and Electrolyte Disorders. 5th edn. New York: McGraw-Hill Book Company; 2001
21. Junqueira LC, Bignolas G, Brentani RR. Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem J 1979;11:447-455 (Pubitemid 9238595)
22. Verroust PJ, Birn H, Nielsen R et al. The tandem endocytic receptors megalin and cubilin are important proteins in renal pathology. Kidney Int 2002;62:745-756 (Pubitemid 35316702)
23. Le NH, van der Wal A, van der Bent P et al. Increased activity of activator protein-1 transcription factor components ATF2, c-Jun, and c-Fos in human and mouse autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2005;16:2724-2731
24. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45
25. Carmosino M, Brooks HL, Cai Q et al. Axial heterogeneity of vasopressin-receptor subtypes along the human and mouse collecting duct. Am J Physiol Renal Physiol 2007;292:F351-F360 (Pubitemid 46115930)
26. Dobin A, Kimberling WJ, Pettinger W et al. Segregation analysis of autosomal dominant polycystic kidney disease. Genet Epidemiol 1993;10:189-200 (Pubitemid 23215495)
27. Torres VE, Harris PC. Mechanisms of disease: Autosomal dominant and recessive polycystic kidney diseases. Nat Clin Pract Nephrol 2006;2:40-54
28. Bankir L. Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovasc Res 2001;51:372-390 (Pubitemid 32718586)
29. Szinnai G, Morgenthaler NG, Berneis K et al. Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. J Clin Endocrinol Metab 2007;92:3973-3978 (Pubitemid 47607649)
30. Morgenthaler NG, Struck J, Jochberger S et al. Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab 2008;19:43-49 (Pubitemid 351317895)
31. Ruggenenti P, Remuzzi A, Ondei P et al. Safety and efficacy of longacting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 2005;68:206-216 (Pubitemid 43181378)
32. van Keimpema L, Nevens F, Vanslembrouck R et al. Lanreotide reduces the volume of polycystic liver: a randomized, doubleblind, placebo-controlled trial. Gastroenterology 2009;137:1661-1668
33. Hogan MC, Masyuk TV, Page LJ et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 2010;21:1052-1061
34. Perico N, Antiga L, Caroli A et al. Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol 2010;21:1031-1040
35. Serra AL, Poster D, Kistler AD et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 2010;63:820-829
36. Walz G, Budde K, Mannaa M et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2010;63:830-840